Under fire from Shire, Roche grabs the VIP lane for top drug prospect emicizumab
Fighting off a flank attack in the courts by attorneys for rival Shire, Roche says it was flagged for the FDA’s inside regulatory track for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
